Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:activities |
gptkb:VRE
Gram-positive bacteria MRSA |
| gptkbp:approves |
gptkb:2000
gptkb:FDA |
| gptkbp:atccode |
J01 XX08
|
| gptkbp:bioavailability |
100% (oral)
|
| gptkbp:brand |
gptkb:Zyvox
|
| gptkbp:casnumber |
165800-03-3
|
| gptkbp:category |
gptkb:unknown
gptkb:C |
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
gptkb:pheochromocytoma
uncontrolled hypertension hypersensitivity to linezolid |
| gptkbp:dosage_form |
oral tablet
IV solution 600 mg twice daily |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
gptkb:tablet
suspension injection |
| https://www.w3.org/2000/01/rdf-schema#label |
Zyvox
|
| gptkbp:indication |
gptkb:pneumonia
sepsis skin infections community-acquired pneumonia endocarditis diabetic foot infections osteomyelitis hospital-acquired pneumonia intra-abdominal infections bacterial infections in patients with HIV/ AIDS complicated skin and skin structure infections |
| gptkbp:interacts_with |
MAO inhibitors
serotonergic drugs adrenergic agents |
| gptkbp:invention |
gptkb:2023
|
| gptkbp:lifespan |
4 to 5 hours
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketed_as |
gptkb:Zyvox
|
| gptkbp:mechanism_of_action |
inhibits bacterial protein synthesis
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:previous_name |
linezolid
|
| gptkbp:route_of_administration |
oral
intravenous |
| gptkbp:side_effect |
headache
nausea diarrhea insomnia thrombocytopenia |
| gptkbp:structure |
C16 H19 FN4 O4 S
|
| gptkbp:used_for |
treatment of bacterial infections
|
| gptkbp:bfsParent |
gptkb:Cephalon
|
| gptkbp:bfsLayer |
5
|